[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFIcJOO1aIEHGKMZwlKakOneuoHwdRdFfA4DZwnLBQp4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":51,"rows":58},"Fundación EPIC",[4],48,false,30,0,20906,5,43,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Coronary Artery Disease",25,{"name":18,"count":19},"Ischemic Heart Disease",18,{"name":21,"count":22},"Coronary Artery Disease (CAD)",8,{"name":24,"count":25},"Cardiovascular Diseases",6,{"name":27,"count":11},"Coronary Disease",{"name":29,"count":30},"Acute Coronary Syndrome",3,{"name":32,"count":30},"Arterial Occlusive Diseases",{"name":34,"count":30},"Aortic Valve Stenosis",[36,41,46],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05030818","Cross-over Study of Coronary Risk Factors With a Polypill","2026-03-30","Polypill of acetylsalicylic acid, ramipril and atorvastatin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06620757","Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry","2026-10-01","Single antiplatelet therapy",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04654052","VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome","2026-12-03","Clopidogrel",[52,53,54,55,56,57],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[59,85,103,126,144,166,193],{"intervention":50,"totalTrials":60,"cells":61},1,{"EARLY_PHASE1":62,"PHASE1":64,"PHASE2":66,"PHASE3":68,"PHASE4":70,"NA":83},{"trials":63,"activeCount":9},[],{"trials":65,"activeCount":9},[],{"trials":67,"activeCount":9},[],{"trials":69,"activeCount":9},[],{"trials":71,"activeCount":60,"soonestReadout":49},[72],{"nctId":47,"briefTitle":48,"status":73,"phases":74,"primaryCompletion":49,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":81},"ACTIVE_NOT_RECRUITING",[56],"2026-12-04","2021-07-02",634,[29,79,15,80],"Acute Myocardial Infarction","Percutaneous Coronary Intervention",[50,82],"Previous treatment",{"trials":84,"activeCount":9},[],{"intervention":82,"totalTrials":60,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":95,"NA":101},{"trials":88,"activeCount":9},[],{"trials":90,"activeCount":9},[],{"trials":92,"activeCount":9},[],{"trials":94,"activeCount":9},[],{"trials":96,"activeCount":60,"soonestReadout":49},[97],{"nctId":47,"briefTitle":48,"status":73,"phases":98,"primaryCompletion":49,"completion":75,"start":76,"enrollment":77,"conditions":99,"interventions":100},[56],[29,79,15,80],[50,82],{"trials":102,"activeCount":9},[],{"intervention":40,"totalTrials":60,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":124},{"trials":106,"activeCount":9},[],{"trials":108,"activeCount":9},[],{"trials":110,"activeCount":9},[],{"trials":112,"activeCount":9},[],{"trials":114,"activeCount":60,"soonestReadout":39},[115],{"nctId":37,"briefTitle":38,"status":116,"phases":117,"primaryCompletion":39,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":122},"RECRUITING",[56],"2026-04-30","2022-10-14",88,[15],[40,123],"Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin",{"trials":125,"activeCount":9},[],{"intervention":123,"totalTrials":60,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":142},{"trials":129,"activeCount":9},[],{"trials":131,"activeCount":9},[],{"trials":133,"activeCount":9},[],{"trials":135,"activeCount":9},[],{"trials":137,"activeCount":60,"soonestReadout":39},[138],{"nctId":37,"briefTitle":38,"status":116,"phases":139,"primaryCompletion":39,"completion":118,"start":119,"enrollment":120,"conditions":140,"interventions":141},[56],[15],[40,123],{"trials":143,"activeCount":9},[],{"intervention":45,"totalTrials":60,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":156},{"trials":147,"activeCount":9},[],{"trials":149,"activeCount":9},[],{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[],{"trials":157,"activeCount":60,"soonestReadout":44},[158],{"nctId":42,"briefTitle":43,"status":116,"phases":159,"primaryCompletion":44,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},[],"2027-10-01","2024-10-10",234,[164],"Atrial Fibrillation",[45],{"intervention":167,"totalTrials":60,"cells":168},"Drug-mediated hyperemia",{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":170,"activeCount":9},[],{"trials":172,"activeCount":9},[],{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":9},[],{"trials":180,"activeCount":9},[181],{"nctId":182,"briefTitle":183,"status":184,"phases":185,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":192},"NCT04685941","Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia","COMPLETED",[57],"2022-10-31","2021-01-25",67,[190,191],"Coronary Microvascular Disease","Myocardial Infarction",[167],{"intervention":194,"totalTrials":60,"cells":195},"Essential pro",{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":206},{"trials":197,"activeCount":9},[],{"trials":199,"activeCount":9},[],{"trials":201,"activeCount":9},[],{"trials":203,"activeCount":9},[],{"trials":205,"activeCount":9},[],{"trials":207,"activeCount":9},[208],{"nctId":209,"briefTitle":210,"status":184,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"NCT05292092","Essential Pro PMCF Study ( rEPIC04E )",[],"2025-12-29","2026-01-18","2022-09-26",161,[21,18],[194]]